文章：

侵袭性非霍奇金淋巴瘤患者膈下区域受累野放疗与受累部位放疗的长期疗效比较——单中心经验

Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience

原文发布日期：2 February 2024

DOI: 10.3390/cancers16030649

类型: Article

开放获取: 是

英文摘要：

(1) Background: This study aimed to examine the difference in efficacy and toxicity of involved-field (IFRT) and involved-site radiotherapy (ISRT) fields in infradiaphragmal aggressive non-Hodgkin lymphoma patients. (2) Methods: In total, 140 patients with infradiaphragmal lymphoma treated between 2003 and 2020 were retrospectively evaluated. There were 69 patients (49%) treated with IFRT, and 71 (51%) patients treated with ISRT. The median dose in the IFRT group was 36 Gy, (range 4–50.4 Gy), and in the ISRT group, it was 30 Gy (range 4–48 Gy). (3) Results: The median follow-up in the IFRT group was 133 months (95% CI 109–158), and in the ISRT group, it was 48 months (95% CI 39–57). In the IFRT group, locoregional control was 67%, and in the ISRT group, 73%. The 2- and 5-year overall survival (OS) in the IFRT and ISRT groups were 79% and 69% vs. 80% and 70%, respectively (p= 0.711). The 2- and 5-year event-free survival (EFS) in the IFRT and ISRT groups were 73% and 68% vs. 77% and 70%, respectively (p= 0.575). Acute side effects occurred in 43 (31%) patients, which is more frequent in the IFRT group, 34 (39%) patients, than in the ISRT group, 9 (13%) patients,p> 0.01. Late toxicities occurred more often in the IFRT group of patients, (10/53) 19%, than in the ISRT group of patients, (2/37) 5%, (p= 0.026). (4) Conclusions: By reducing the radiotherapy volume and the doses in the treatment of infradiaphragmatic fields, treatment with significantly fewer acute and long-term side effects is possible. At the same time, efficiency and local disease control are not compromised.

摘要翻译： 

（1）背景：本研究旨在比较膈下侵袭性非霍奇金淋巴瘤患者中，累及野放疗（IFRT）与累及部位放疗（ISRT）在疗效和毒性方面的差异。（2）方法：回顾性分析了2003年至2020年间接受治疗的140例膈下淋巴瘤患者。其中69例（49%）接受IFRT治疗，71例（51%）接受ISRT治疗。IFRT组中位放疗剂量为36 Gy（范围4–50.4 Gy），ISRT组中位剂量为30 Gy（范围4–48 Gy）。（3）结果：IFRT组中位随访时间为133个月（95% CI 109–158），ISRT组为48个月（95% CI 39–57）。IFRT组局部区域控制率为67%，ISRT组为73%。IFRT组与ISRT组的2年及5年总生存率分别为79%和69%对比80%和70%（p=0.711）；2年及5年无事件生存率分别为73%和68%对比77%和70%（p=0.575）。共43例（31%）患者出现急性副作用，其中IFRT组发生率更高（34例，39%），显著高于ISRT组（9例，13%）（p>0.01）。晚期毒性发生率在IFRT组（10/53，19%）也高于ISRT组（2/37，5%）（p=0.026）。（4）结论：在膈下区域放疗中，通过缩小照射范围和降低剂量，可显著减少急性及长期副作用，同时不损害治疗效果及局部疾病控制。

原文链接：

Long-Term Results of IFRT vs. ISRT in Infradiaphragmal Fields in Aggressive Non-Hodgkins’s Lymphoma Patients—A Single Centre Experience